Beta
Adolescent
Adrenergic beta-Agonists
/ pharmacology
Adult
Blood Glucose
/ metabolism
Clenbuterol
/ pharmacology
Cyclic AMP-Dependent Protein Kinases
/ metabolism
Energy Metabolism
/ drug effects
Humans
Lactic Acid
/ metabolism
Lipid Peroxidation
/ drug effects
Male
Muscle, Skeletal
/ metabolism
Phosphorylation
/ drug effects
Potassium
/ blood
Quadriceps Muscle
/ physiology
Signal Transduction
/ drug effects
TOR Serine-Threonine Kinases
/ metabolism
Young Adult
anabolic
doping
muscle growth
muscle hypertrophy
wada
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
01
10
2019
revised:
13
12
2019
accepted:
19
12
2019
pubmed:
31
12
2019
medline:
26
1
2021
entrez:
31
12
2019
Statut:
ppublish
Résumé
Clenbuterol is a beta
Substances chimiques
Adrenergic beta-Agonists
0
Blood Glucose
0
Lactic Acid
33X04XA5AT
MTOR protein, human
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Cyclic AMP-Dependent Protein Kinases
EC 2.7.11.11
Potassium
RWP5GA015D
Clenbuterol
XTZ6AXU7KN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-618Subventions
Organisme : Anti Doping Denmark
ID : N/A
Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010;160(5):1048-1061.
Fischer J., Ganellin CR. Analogue-based drug discovery. Weinheim: Wiley-VCH; 2006.
Huckins DS, Lemons MF. Myocardial ischemia associated with clenbuterol abuse: report of two cases. J Emerg Med. 2013;44(2):444-449.
Lehmann S, Thomas A, Schiwy-Bochat KH, et al. Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). Forensic Sci Int. 2019;303:1-7, 109925.
Parr MK, Koehler K, Geyer H, Guddat S, Schanzer W. Clenbuterol marketed as dietary supplement. Biomed Chromatogr. 2008;22(3):298-300.
Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus. 2013;34(3):306-312.
Waight M, McGuinness W. Case of low dose clenbuterol toxicity. BMJ Case Rep. 2016;2016:1-3. https://doi.org/10.1136/bcr-2016-215157
World Anti-Doping Agency. Anti-Doping Testing Figures. https://www.wada-ama.org/en/resources/laboratories/anti-doping-testing-figures-report. .
World Anti-Doping Agency. Stakeholder notice regarding meat contamination. https://www.wada-ama.org/sites/default/files/resources/files/2019-05-30-meat_contamination_notice_final.pdf. .
Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep. 1984;4(1):83-91.
Hinkle RT, Hodge KM, Cody DB, et al. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve. 2002;25(5):729-734.
MacLennan PA, Edwards RH. Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem J. 1989;264(2):573-579.
Oishi Y, Imoto K, Ogata T, Taniguchi K, Matsumoto H, Roy RR. Clenbuterol induces expression of multiple myosin heavy chain isoforms in rat soleus fibres. Acta Physiol Scand. 2002;176(4):311-318.
Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation. 1995;92(9 Suppl):II483-II489.
Bodymedia.com. Clenbuterol REVIEW (2019)|Uses - Side Effects - Alternatives. https://bodymedia.com/clenbuterol-review/#3_The_12_weeks_cycle. .
Bergström J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35(7):609-616.
Onslev J, Jacobson G, Narkowicz C, et al. Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men. Eur J Appl Physiol. 2017;117(9):1907-1915.
Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism. 1988;37(3):287-301.
Hostrup M, Kalsen A, Onslev J, et al. Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic beta2-adrenergic stimulation in men. J Appl Physiol (1985). 2015;119(5):475-486.
Bachasson D, Millet GY, Decorte N, Wuyam B, Levy P, Verges S. Quadriceps function assessment using an incremental test and magnetic neurostimulation: a reliability study. J Electromyogr Kinesiol. 2013;23(3):649-658.
Strojnik V, Komi PV. Neuromuscular fatigue after maximal stretch-shortening cycle exercise. J Appl Physiol (1985). 1998;84(1):344-350.
Thomassen M, Hostrup M, Murphy RM, et al. Abundance of ClC-1 chloride channel in human skeletal muscle: fiber type specific differences and effect of training. J Appl Physiol (1985). 2018;125(2):470-478.
Lee P, Birzniece V, Umpleby AM, Poljak A, Ho KK. Formoterol, a highly beta2-selective agonist, induces gender-dimorphic whole body leucine metabolism in humans. Metabolism. 2015;64(4):506-512.
Lee P, Day RO, Greenfield JR, Ho KK. Formoterol, a highly beta2-selective agonist, increases energy expenditure and fat utilisation in men. Int J Obes (Lond). 2013;37(4):593-597.
Hoeks J, van Baak MA, Hesselink MK, et al. Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab. 2003;285(4):E775-E782.
Oomen JM, van Rossum CT, Hoebee B, Saris WH, van Baak MA. Beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005;90(4):2301-2307.
Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobiodyn. 1985;8(5):385-391.
Yang YG, Song LX, Jiang N, Xu XT, di XH, Zhang M. Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. Int J Clin Exp Med. 2015;8(10):18744-18750.
Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della CG. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol. 1999;55(2):131-138.
Jacobson GA, Yee KC, Wood-Baker R, Walters EH. SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015;7(2):109-113.
Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism. 1994;43(9):1119-1125.
Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta2-adrenoceptor activation. Am J Physiol. 1992;263(1 Pt 1):E50-E56.
Hostrup M, Narkowicz CK, Habib S, Nichols DS, Jacobson GA. Beta2-adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular PKA signaling at therapeutic inhaled doses. Drug Test Anal. 2019;11(7):1048-1056.
Hostrup M, Reitelseder S, Jessen S, et al. Beta2-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. J Physiol. 2018;596(17):4121-4139.
Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol (1985). 2007;102(2):740-747.
Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB. Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. J Appl Physiol (1985). 2009;106(4):1374-1384.
Jessen S, Onslev J, Lemminger A, Backer V, Bangsbo J, Hostrup M. Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: a randomized controlled trial. Scand J Med Sci Sports. 2018;28(10):2114-2122.
Lemminger AK, Jessen S, Habib S, et al. Effect of beta2-adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men. Scand J Med Sci Sports. 2019;29(12):1881-1891.
Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond). 1993;84(6):651-654.
Kamalakkannan G, Petrilli CM, George I, et al. Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transplant. 2008;27(4):457-461.
Onslev J, Jensen J, Bangsbo J, Wojtaszewski J, Hostrup M. Beta2-agonist induces net leg glucose uptake and free fatty acid release at rest but not during exercise in young men. J Clin Endocrinol Metab. 2019;104(3):647-657.
Haffner CA, Kendall MJ, Maxwell S, Hughes B. The lipolytic effect of beta1- and beta2-adrenoceptor activation in healthy human volunteers. Br J Clin Pharmacol. 1993;35(1):35-39.
Hostrup M, Kalsen A, Bangsbo J, et al. High-dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men. Eur J Appl Physiol. 2014;114(12):2499-2508.
Hostrup M, Kalsen A, Ørtenblad N, et al. Beta2-adrenergic stimulation enhances Ca2+ release and contractile properties of skeletal muscles, and counteracts exercise-induced reductions in Na+-K+-ATPase Vmax in trained men. J Physiol. 2014;592(24):5445-5459.
Kalsen A, Hostrup M, Bangsbo J, Backer V. Combined inhalation of beta2-agonists improves swim ergometer sprint performance but not high-intensity swim performance. Scand J Med Sci Sports. 2014;24(5):814-822.
Crivelli G, Borrani F, Capt R, Gremion G, Maffiuletti NA. Actions of beta2-adrenoceptor agonist drug on human soleus muscle contraction. Med Sci Sports Exerc. 2013;45(7):1252-1260.
Crivelli G, Maffiuletti NA. Actions of beta2-adrenoceptor agonist drug on neuromuscular function after fatigue. Med Sci Sports Exerc. 2014;46(2):247-256.
McCormick C, Alexandre L, Thompson J, Mutungi G. Clenbuterol and formoterol decrease force production in isolated intact mouse skeletal muscle fiber bundles through a beta2-adrenoceptor-independent mechanism. J Appl Physiol (1985). 2010;109(6):1716-1727.
Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. West J Med. 1982;137(5):379-399.
White M, Roden R, Minobe W, et al. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation. 1994;90(3):1225-1238.
Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. Am J Physiol Heart Circ Physiol. 2005;289(1):H344-H349.
Xiao RP, Tomhave ED, Wang DJ, et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest. 1998;101(6):1273-1282.
Koeberl DD, Case LE, Smith EC, et al. Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. Mol Ther. 2018;26(9):2304-2314. https://doi.org/10.1016/j.ymthe.2018.06.023